Nothing Special   »   [go: up one dir, main page]

DK0674510T3 - Injicerbart præparat omfattende paclitaxel - Google Patents

Injicerbart præparat omfattende paclitaxel

Info

Publication number
DK0674510T3
DK0674510T3 DK94901593T DK94901593T DK0674510T3 DK 0674510 T3 DK0674510 T3 DK 0674510T3 DK 94901593 T DK94901593 T DK 94901593T DK 94901593 T DK94901593 T DK 94901593T DK 0674510 T3 DK0674510 T3 DK 0674510T3
Authority
DK
Denmark
Prior art keywords
taxol
solution
paclitaxel
injectable preparation
acid
Prior art date
Application number
DK94901593T
Other languages
English (en)
Inventor
David R Carver
Timothy R Prout
Hernita Ewald
Robyn Elliott
Paul Handreck
Original Assignee
Napro Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25644377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0674510(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Napro Biotherapeutics Inc filed Critical Napro Biotherapeutics Inc
Application granted granted Critical
Publication of DK0674510T3 publication Critical patent/DK0674510T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK94901593T 1992-11-27 1993-11-18 Injicerbart præparat omfattende paclitaxel DK0674510T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPL607492 1992-11-27
US99550192A 1992-12-22 1992-12-22
PCT/US1993/011209 WO1994012031A1 (en) 1992-11-27 1993-11-18 Injectable composition

Publications (1)

Publication Number Publication Date
DK0674510T3 true DK0674510T3 (da) 1999-05-10

Family

ID=25644377

Family Applications (2)

Application Number Title Priority Date Filing Date
DK94901593T DK0674510T3 (da) 1992-11-27 1993-11-18 Injicerbart præparat omfattende paclitaxel
DK97121710T DK0835657T3 (da) 1992-11-27 1993-11-18 Stabil, injicerbar paclitaxelsammensætning

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97121710T DK0835657T3 (da) 1992-11-27 1993-11-18 Stabil, injicerbar paclitaxelsammensætning

Country Status (12)

Country Link
US (7) US5733888A (da)
EP (4) EP1384474A1 (da)
JP (1) JP2880292B2 (da)
AT (2) ATE169216T1 (da)
AU (1) AU5612694A (da)
CA (2) CA2149150C (da)
DE (2) DE69320206T2 (da)
DK (2) DK0674510T3 (da)
ES (2) ES2224200T3 (da)
GR (1) GR3027724T3 (da)
PT (1) PT835657E (da)
WO (2) WO1994012031A1 (da)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0674510T3 (da) * 1992-11-27 1999-05-10 Napro Biotherapeutics Inc Injicerbart præparat omfattende paclitaxel
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
FR2710534B1 (fr) * 1994-09-28 1996-07-05 Bristol Myers Squibb Co Solvant de stabilisation, composition pharmaceutique le contenant, et son procédé de préparation.
NL9500340A (nl) * 1995-02-22 1996-10-01 Yew Tree Pharmaceuticals B V Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat.
DE19536165A1 (de) * 1995-09-28 1997-04-03 Basf Ag Verfahren zur Reinigung von alkoxylierten Fetten
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
AU724842B2 (en) * 1995-12-21 2000-09-28 Genelabs Technologies, Inc. Taxane composition and method
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
AU741439B2 (en) 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6388112B1 (en) 1998-10-20 2002-05-14 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceutical compositions
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
KR100856353B1 (ko) 1999-05-14 2008-09-04 니리어스 파마슈티컬즈, 인크. 신규한 인터루킨-1 및 종양사멸인자-α의 조절인자들,상기 조절인자들의 합성 및 상기 조절인자들의 사용 방법
DE19925211B4 (de) * 1999-06-01 2006-01-12 PBS Pharmaceutical Bulk Substances SA Kit zur Herstellung einer Formulierung von Paclitaxel
CO5271755A1 (es) * 2000-01-20 2003-04-30 Baker Norton Pharma Purificacion de aceites de castor polioxietilados con carbon activado
MXPA01009900A (es) * 2000-02-02 2003-08-20 Univ Florida State Res Found Formulaciones de taxano que tienen solubilidad mejorada.
JP2003523769A (ja) * 2000-02-23 2003-08-12 ヴァーテックス ファーマシューティカルズ （サンディエゴ）エルエルシー 改変された蛍光タンパク質
JP4922507B2 (ja) * 2000-08-10 2012-04-25 武田薬品工業株式会社 医薬組成物
US6951885B2 (en) 2000-08-10 2005-10-04 Takeda Pharmaceutical Company Limited Pharmaceutical composition
US7144723B2 (en) * 2000-11-16 2006-12-05 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product discovery
US6919370B2 (en) 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
AU2002303210A1 (en) 2001-04-06 2002-10-21 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
JP2005515187A (ja) * 2001-11-26 2005-05-26 スーパージェン インコーポレイテッド ポリオキシエチル化ひまし油を使用する医薬組成物の調製方法
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
EP1465618A2 (en) * 2001-12-20 2004-10-13 Bristol-Myers Squibb Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
ATE444062T1 (de) * 2002-06-26 2009-10-15 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
MXPA05001217A (es) * 2002-08-02 2005-05-16 Nereus Pharmaceuticals Inc Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
AU2003296908A1 (en) * 2002-09-27 2004-05-04 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
WO2004043390A2 (en) * 2002-11-08 2004-05-27 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
WO2004072104A2 (en) * 2003-02-11 2004-08-26 Northwestern University Methods and materials for nanocrystalline surface coatings and attachment of peptide amphiphile nanofibers thereon
DE602004031614D1 (de) * 2003-06-20 2011-04-14 Nereus Pharmaceuticals Inc Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
US8217072B2 (en) * 2003-06-20 2012-07-10 The Regents Of The University Of California Salinosporamides and methods for use thereof
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
DE602004020506D1 (de) * 2003-12-12 2009-05-20 Quiral Quimica Do Brasil Verfahren zur herstellung von wasserfreien und hydratisierten pharmazeutischen wirkstoffen (apis); aus diesen hergestellte stabile pharmazeutische zusammensetzungen und anwendungen für diese zusammensetzungen
EP1711486B1 (en) * 2004-01-23 2011-05-11 Nereus Pharmaceuticals, Inc. Bis-indole pyrroles useful as antimicrobial agents
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
AU2005283141B2 (en) 2004-04-30 2012-05-10 Nereus Pharmaceuticals, Inc. (3.2.0) heterocyclic compounds and methods of using the same
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
WO2006060676A1 (en) 2004-12-03 2006-06-08 Dana Farber Cancer Institute Compositions and methods for treating neoplastic diseases
WO2006126825A1 (en) * 2005-05-23 2006-11-30 Choongwae Pharma Corporation Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection
EP1904052A4 (en) * 2005-06-17 2008-12-10 Hospira Australia Pty Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF DOCATEXEL
CA2613366A1 (en) 2005-07-21 2007-02-08 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators
JP5461837B2 (ja) * 2005-08-31 2014-04-02 アブラクシス バイオサイエンス， エルエルシー 難水溶性医薬品および抗菌剤を含む組成物
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
CN100548274C (zh) * 2006-01-12 2009-10-14 永信药品工业股份有限公司 紫杉醇水性注射液及其制备方法
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
FR2912745A1 (fr) * 2007-02-19 2008-08-22 Centre Nat Rech Scient Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
AU2009246467A1 (en) 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8128951B2 (en) * 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
NZ603828A (en) 2010-05-03 2015-09-25 Teikoku Pharma Usa Inc Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012130819A1 (en) 2011-03-29 2012-10-04 Sanofi Otamixaban formulations with improved stability
US20140234345A1 (en) * 2011-07-11 2014-08-21 Biolyse Pharma Corporation Novel anti-cancer isocarbostyril alkaloid conjugates
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EP2968390A4 (en) * 2013-03-15 2016-10-26 Epizyme Inc INJECTABLE FORMULATIONS FOR THE TREATMENT OF CANCER
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices
US9375408B2 (en) 2014-09-02 2016-06-28 Bhupinder Singh Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
EP3193879A4 (en) * 2014-09-17 2018-05-16 Epizyme, Inc. Injectable formulations for treating cancer
IL312208A (en) 2014-10-08 2024-06-01 Pacific Northwest Res Institute Methods and preparations for increasing the potency of antifungal agents
HK1249051A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治療腦腫瘤的方法
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
AU2016291708B2 (en) 2015-07-13 2020-12-24 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
US10561766B2 (en) 2015-09-15 2020-02-18 W. L. Gore & Associates, Inc. Drug composition and coating
RU2753543C1 (ru) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Композиции, содержащие тукаресол или его аналоги
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
MX2019009020A (es) 2017-02-01 2019-11-12 Beyondspring Pharmaceuticals Inc Metodo para reducir la neutropenia.
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
EP3773612A4 (en) 2018-03-28 2022-01-12 Herbalife International of America, Inc. ACETYLATION OF POLYSACCHARIDS
CN111770752A (zh) * 2018-10-16 2020-10-13 美国纳米食品药品公司 瘤内注射制剂
PH12022552732A1 (en) 2020-04-13 2024-03-25 US Nano Food & Drug INC Basic chemotherapeutic intratumour injection formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS552421B2 (da) * 1971-08-06 1980-01-19
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5157049A (en) * 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
ATE129006T1 (de) * 1990-02-15 1995-10-15 Pq Corp Verfahren zur behandlung von bratöl unter verwendung einer aluminiumoxid- und amorphen kieselerdezusammensetzung.
TW223634B (da) * 1991-03-18 1994-05-11 Kingston David G I
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
DK0674510T3 (da) * 1992-11-27 1999-05-10 Napro Biotherapeutics Inc Injicerbart præparat omfattende paclitaxel
US5281727A (en) * 1992-11-27 1994-01-25 Napro Biotherapeutics, Inc. Method of using ion exchange media to increase taxane yields
WO1994012198A1 (en) * 1992-11-27 1994-06-09 F.H. Faulding & Co. Limited Injectable taxol composition
HU213200B (en) 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5733388A (en) 1994-08-11 1998-03-31 Daido Tokiushuko Kabushiki Kaisha Steel composition for bearings and method of producing the same

Also Published As

Publication number Publication date
US20040204479A1 (en) 2004-10-14
WO1994012030A1 (en) 1994-06-09
CA2149150A1 (en) 1994-06-09
AU5612694A (en) 1994-06-22
DE69333605T2 (de) 2005-02-03
ATE274347T1 (de) 2004-09-15
US6140359A (en) 2000-10-31
US5977164A (en) 1999-11-02
US20030065022A1 (en) 2003-04-03
US5972992A (en) 1999-10-26
EP1384474A1 (en) 2004-01-28
US6306894B1 (en) 2001-10-23
DE69320206D1 (de) 1998-09-10
DK0835657T3 (da) 2005-01-10
JP2880292B2 (ja) 1999-04-05
ES2119996T3 (es) 1998-10-16
JPH08503945A (ja) 1996-04-30
GR3027724T3 (en) 1998-11-30
ATE169216T1 (de) 1998-08-15
CA2149150C (en) 2000-08-01
EP0674510A1 (en) 1995-10-04
US6770670B2 (en) 2004-08-03
EP1500393A1 (en) 2005-01-26
DE69320206T2 (de) 1999-02-11
EP0674510B1 (en) 1998-08-05
EP0674510A4 (en) 1995-08-12
DE69333605D1 (de) 2004-09-30
EP0835657A1 (en) 1998-04-15
PT835657E (pt) 2004-11-30
EP0835657B1 (en) 2004-08-25
WO1994012031A1 (en) 1994-06-09
CA2308082A1 (en) 1994-06-09
ES2224200T3 (es) 2005-03-01
US5733888A (en) 1998-03-31

Similar Documents

Publication Publication Date Title
DK0674510T3 (da) Injicerbart præparat omfattende paclitaxel
ATE201328T1 (de) Hochkonzentriertes immunglobulin-präparat und verfahren zu seiner herstellung
DK47189A (da) Bredspektret konserveringsmiddel med synergistisk biocidvirkning
NO307205B1 (no) Preparater basert på virkestoffer fra taxanklassen samt perfusjonspreparater inneholdende disse
ATE98473T1 (de) Orale praeparate gegen zahnbelaege.
ZA924926B (en) Cosmetic composition
NO964433L (no) Farmasöytiske preparater på basis av derivater av taxanklassen
DE3682208D1 (de) Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.
ATE148630T1 (de) Stabilisierte derivate von vitamin d2 und d3 enthaltende pharmazeutische zusammensetzungen
ATE225340T1 (de) Einschlusskomplexe von taxol oder taxotere oder taxus-extrakten und cyclodextrinen, ihre herstellung und ihre verwendung
ATE82139T1 (de) Eine lipidloesliche substanz enthaltende waessrige fluessigkeit.
HUT66153A (en) Pharmaceutical compositions which can be used for preventing and treating of chemotherapy-induced alopecia
DE3671168D1 (de) Pharmazeutische zubereitung.
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
SE8503447D0 (sv) Farmaceutiska och kosmetiska kompositioner, innehallande dihydroxi-1,8-fenyl-10-antron-9 som verksam bestandsdel, samt sett att framstella den verksamma foreningen
KR860003012A (ko) (-)시스-1,2-에폭시프로필포스폰산과 아미노산과의 염을 함유하는 수용성 제약 조성물
KR930000116A (ko) 돼지 흉막 폐렴 예방/치료 조성물